Generics

  • Generics lift Endo’s 3Q

    CHADDS FORD, Pa. Strong generic sales helped Endo edge analyst expectations for the third quarter, the company noted.

    Net income reached $54.2 million, compared with $49.4 million during the period ended Sept. 30. Net sales jumped 23% to $444.1 million, versus $361 million during the same period a year ago. Analysts had estimated sales of $443.36 million for the quarter.

  • Watson to market, distribute authorized generic ADHD drug

    MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals will distribute an authorized generic version of a drug used to treat attention deficit hyperactivity disorder, Watson said Tuesday.

    Watson entered an agreement with Johnson & Johnson subsidiary Ortho-McNeil-Janssen Pharmaceuticals to distribute an authorized generic of Concerta (methylphenidate hydrochloride) extended-release tablets. An authorized generic is a branded drug sold under its generic name, usually by a third-party company.

  • Sandoz introduces generic Zosyn

    PRINCETON, N.J. Sandoz has launched a generic antibiotic drug, the generics division of Swiss drug maker Novartis said Thursday.

     

    Sandoz announced the launch of piperacillin and tazobactam for injection. The drug is used to treat moderate to severe infections of bacteria resistant to piperacillin alone but vulnerable to the combination of the two drugs.

     

     

  • Hospira's generic Zosyn enters market

    LAKE FOREST, Ill. Drug maker Hospira has launched a generic treatment for bacterial infections, Hospira said Thursday.

     

    The company, which specializes in generic injectables, announced the launch of piperacillin and tazobactam for injection. The drug is a generic version of Pfizer’s Zosyn.

     

     

    Various versions of the drug had sales of $797 million during the 12-month period ended in August, according to IMS Health. Sandoz, the generics division of Novartis, also launched its own version of the drug Thursday.

  • Mylan gets nod for additional strengths of generic Mirapex

    PITTSBURGH The Food and Drug Administration has approved a Mylan generic drug for Parkinson’s disease, Mylan said Thursday.

     

    The drug maker announced the approval of pramipexole dihydrochloride tablets in the 0.125-mg, 0.25-mg, 0.5-mg, 1-mg and 1.5-mg strengths. The drug is a generic version of Boehringer Ingelheim’s Mirapex.

     

     

  • Report: FDA may consider strengthening generic drug regulations

    BETHESDA, Md. The Food and Drug Administration could decide that some generic drugs are not equivalent to their branded counterparts, according to published reports.

     

  • K-V establishes generic drug subsidiary Nesher Pharmaceuticals

    ST. LOUIS K-V Pharmaceutical has created a new marketing subsidiary for generic drugs, the company said Wednesday.

     

    K-V announced the establishment of Nesher Pharmaceuticals, appointing as its president Mark Hartman, who has had several positions in generic drug companies.

     

     

  • Dr. Reddy's to launch generic Prevacid

    HYDERABAD, India Dr. Reddy's disclosed on Tuesday it will market a generic peptic ulcer treatment.

    Dr. Reddy's lansoprazole delayed-release capsules will be available in 15-mg and 30-mg strengths, the drug maker said. The capsules are the generic version of Takeda's Prevacid delayed-release capsules.

    The FDA approved Dr. Reddy’s abbreviated new drug application for the drug on Oct. 15.

X
This ad will auto-close in 10 seconds